Mets-IR as a predictor of cardiovascular events in the middle-aged and elderly population and mediator role of blood lipids.
CHARLS
METS-IR
cardiovascular disease
heart disease
stroke
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
05
2023
accepted:
22
06
2023
medline:
4
8
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
Cardiovascular disease (CVD) is a global health concern, with a significant impact on morbidity and mortality rates. Using fasting glucose, fasting triglycerides, body mass index (BMI), and high-density lipoprotein cholesterol (HDL-C), the metabolic score of insulin resistance (Mets-IR), a novel index created by Mexican researchers to assess insulin sensitivity, is a more precise way to measure insulin sensitivity. This study aimes to explore the association between Mets-IR and CVD, as well as investigate the potential mediating role of of low-density lipoprotein cholesterol (LDL-C). The study's data came from the 2011 and 2018 China Health and Retirement Longitudinal Studies (CHARLS). We used three logistic regression models to account for the potential effects of ten factors on cardiovascular disease/stroke/heart disease. Moreover, We performed mediation analyses to evaluate the role of LDL-C in the association between Mets-IR and incident CVD. This study comprised 4,540 participants, of whom 494 (10.88%) were found to develop disease (CVD). Each interquartile range (IQR) increased in Mets-IR raised the risk of developing CVD by 38% (OR=1.38; 95% CI, 1.21-1.56) and there was a linear dose-response relationship between Mets-IR and the risk of new-onset cardiovascular disease, stroke, and heart disease ( ets-IR is associated with an increased risk of cardiovascular disease/stroke/cardiac issues, with LDL-C mediating these relationships. Improving insulin sensitivity and lipid regulation may be essential and effective preventive measures for cardiovascular events.
Sections du résumé
Background
Cardiovascular disease (CVD) is a global health concern, with a significant impact on morbidity and mortality rates. Using fasting glucose, fasting triglycerides, body mass index (BMI), and high-density lipoprotein cholesterol (HDL-C), the metabolic score of insulin resistance (Mets-IR), a novel index created by Mexican researchers to assess insulin sensitivity, is a more precise way to measure insulin sensitivity. This study aimes to explore the association between Mets-IR and CVD, as well as investigate the potential mediating role of of low-density lipoprotein cholesterol (LDL-C).
Methods
The study's data came from the 2011 and 2018 China Health and Retirement Longitudinal Studies (CHARLS). We used three logistic regression models to account for the potential effects of ten factors on cardiovascular disease/stroke/heart disease. Moreover, We performed mediation analyses to evaluate the role of LDL-C in the association between Mets-IR and incident CVD.
Results
This study comprised 4,540 participants, of whom 494 (10.88%) were found to develop disease (CVD). Each interquartile range (IQR) increased in Mets-IR raised the risk of developing CVD by 38% (OR=1.38; 95% CI, 1.21-1.56) and there was a linear dose-response relationship between Mets-IR and the risk of new-onset cardiovascular disease, stroke, and heart disease (
Conclusion
ets-IR is associated with an increased risk of cardiovascular disease/stroke/cardiac issues, with LDL-C mediating these relationships. Improving insulin sensitivity and lipid regulation may be essential and effective preventive measures for cardiovascular events.
Identifiants
pubmed: 37534205
doi: 10.3389/fendo.2023.1224967
pmc: PMC10393118
doi:
Substances chimiques
Cholesterol, LDL
0
Lipids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1224967Informations de copyright
Copyright © 2023 Qian, Sheng, Shen, Fang, Deng and Zou.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Curr Neuropharmacol. 2020;18(11):1138-1153
pubmed: 32282306
Cardiovasc Diabetol. 2022 Jul 1;21(1):123
pubmed: 35778734
Curr Psychiatry Rep. 2016 Nov;18(11):101
pubmed: 27671918
Front Cardiovasc Med. 2022 Jul 29;9:918359
pubmed: 35966520
Endocr Rev. 2019 Dec 1;40(6):1447-1467
pubmed: 31050706
Stroke Vasc Neurol. 2022 Aug;7(4):276-284
pubmed: 35256525
Front Endocrinol (Lausanne). 2022 Mar 18;13:851338
pubmed: 35370984
Am J Physiol. 1979 Sep;237(3):E214-23
pubmed: 382871
Int J Gen Med. 2021 Nov 06;14:7729-7740
pubmed: 34785931
J Am Coll Cardiol. 2021 Jun 22;77(24):3031-3041
pubmed: 34140107
Intern Med J. 2009 Jan;39(1):49-53
pubmed: 19290982
Diabetes Care. 2022 Aug 1;45(8):1863-1872
pubmed: 35700159
Atherosclerosis. 2014 Oct;236(2):257-62
pubmed: 25108074
Angiology. 2021 Nov;72(10):994-1000
pubmed: 33887969
J Endocrinol Invest. 2021 Mar;44(3):631-634
pubmed: 32651893
J Diabetes Investig. 2021 Nov;12(11):2046-2053
pubmed: 33982885
J Pers Med. 2021 Jul 28;11(8):
pubmed: 34442386
BMC Endocr Disord. 2022 Nov 10;22(1):274
pubmed: 36357872
J Clin Invest. 1997 Sep 1;100(5):1230-9
pubmed: 9276741
Am Heart J. 2021 Aug;238:75-84
pubmed: 33961830
Eur J Clin Invest. 2019 Feb;49(2):e13049
pubmed: 30422317
Cardiovasc Diabetol. 2018 Aug 31;17(1):122
pubmed: 30170598
J Clin Invest. 2021 Nov 1;131(21):
pubmed: 34720091
Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1703-8
pubmed: 27283744
Curr Cardiovasc Risk Rep. 2016 Jan;10:
pubmed: 27274775
Curr Diab Rep. 2018 Oct 17;18(12):127
pubmed: 30328521
Eur J Endocrinol. 2018 May;178(5):533-544
pubmed: 29535168
Diabetol Metab Syndr. 2022 Dec 17;14(1):191
pubmed: 36528713
J Am Heart Assoc. 2023 Jan 17;12(2):e026850
pubmed: 36628962